As previously reported, Oppenheimer analyst Leland Gershell started coverage of Acasti Pharma (ACST) with an Outperform rating and $7 price target. While the analyst notes that Vascepa's prospects to serve a multibillion-dollar sales opportunity have driven significant value appreciation for Amarin (AMRN), he believes Acasti Pharma's potentially best-in-class omega-3 is only months away from pivotal readouts in the very high triglycerides niche, and anticipates a REDUCE-IT-like label expansion can be secured without new outcomes data. With shares trading at just a about $100M EV, Gershell believes Acasti holds "considerable upside" as CaPre approaches commercialization, its advantages are better appreciated, and Vascepa's sales growth continues to impress.